SNDX

Fireside Chat Announcement: Syndax Pharmaceuticals will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on April 9, 2025, featuring CEO Michael A. Metzger and the management team, with a live webcast available on their website.

Company Overview: Syndax is a biopharmaceutical company focused on developing innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™, and is actively conducting clinical trials to enhance cancer care.

Revuforj Launch and Sales: JP Morgan's survey highlights the promising launch of Syndax Pharmaceuticals' Revuforj, the first menin inhibitor approved for relapsed/refractory acute leukemias, generating $7.7 million in revenue within its first five weeks on the market.

Market Outlook and Analyst Ratings: Analysts project significant sales growth for Revuforj, estimating around $50 million in 2025, and have raised the stock price target from $39 to $41, indicating that SNDX shares are undervalued based on the drug's potential in treating KMT2A and NPM1 AML.

Inducement Awards Granted: Syndax Pharmaceuticals announced the granting of inducement awards for 282,000 shares of common stock to 12 new employees as part of their 2023 Inducement Plan, with a four-year vesting schedule.

Company Overview: Syndax is a biopharmaceutical company focused on developing innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™, and is actively conducting clinical trials to advance its pipeline.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Fulgent Genetics (FLGT): Analysts maintain a Hold rating with a price target of $16.00, indicating limited upside potential from its current price of $15.28, while the consensus suggests a slight increase to $18.00.

Alignment Healthcare (ALHC) and Syndax Pharmaceuticals (SNDX): Alignment Healthcare receives a Buy rating with a target of $21.00, showing moderate growth potential, whereas Syndax Pharmaceuticals has a Strong Buy consensus with a significant upside target of $35.67.

Financial Performance: Syndax Pharmaceuticals reported $7.7 million in net product revenue from the launch of Revuforj in the first five weeks, with a strong cash position of $692.4 million expected to fund operations until profitability.

Product Developments: The company launched Niktimvo for chronic graft-versus-host disease and plans to file a supplemental NDA for revumenib in R/R mNPM1 AML by Q2 2025, supported by positive trial data.

Earnings Reports Overview: Several companies, including TG Therapeutics, California Resources Corporation, and Burford Capital, are set to report their earnings for the quarter ending December 31, 2024, with varying forecasts indicating potential growth or declines compared to the previous year.

Industry Comparisons: The Price to Earnings ratios for these companies suggest that many are expected to outperform their industry competitors in terms of earnings growth, despite some companies like Surgery Partners and N-able experiencing anticipated decreases in earnings per share.

Investigation of Syndax Pharmaceuticals: Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Syndax Pharmaceuticals, focusing on possible self-dealing that may affect shareholders' rights.

Call to Action for Shareholders: Long-term shareholders are encouraged to contact Kuehn Law for a free consultation regarding potential damages and corporate governance reforms, emphasizing the importance of shareholder involvement in maintaining market integrity.

Kura Oncology's Stock Reaction: Kura Oncology's stock fell approximately 9% despite announcing a successful mid-stage trial for their menin inhibitor ziftomenib in treating acute myeloid leukemia, while Syndax Pharma's similar drug candidate saw an increase in its stock price.

Future Plans and Comparisons: Kura and Kyowa Kirin plan to submit a New Drug Application for ziftomenib in Q2 2025, while Syndax's revumenib has already been approved by the FDA and is expected to seek label expansion for a related condition in H1 2025.

Analyst Ratings: Barclays analyst Peter Lawson has maintained a Buy rating on Syndax Pharmaceuticals (SNDX) with a price target of $33.00, while the current analyst consensus is a Strong Buy with an average price target of $36.80, indicating a potential upside of 151.19%.

Company Performance: Syndax Pharmaceuticals' shares closed at $14.65, with a one-year high of $25.34 and a low of $12.06, and the company has an average trading volume of 2.49 million shares.

Inducement Awards Announcement: Syndax Pharmaceuticals granted inducement awards for 124,000 shares of common stock to six new employees under its 2023 Inducement Plan, with a four-year vesting schedule.

Company Overview: Syndax is a biopharmaceutical company focused on innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™, and is actively conducting clinical trials.

Upcoming Investor Conferences: Syndax Pharmaceuticals will participate in the Guggenheim SMID Cap Biotech Conference on February 6, 2025, and Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025, with live webcasts available on their website.

Company Overview: Syndax is a biopharmaceutical company focused on developing innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™, and is conducting several clinical trials to enhance cancer care.

FDA Approval of Niktimvo: Incyte and Syndax Pharmaceuticals announced that the FDA has approved Niktimvo (axatilimab-csfr) for treating chronic graft-versus-host disease (GVHD) in patients who have failed at least two prior therapies, with availability expected in early February.

Dosage and Administration: The approved dosage for Niktimvo is 0.3 mg/kg, up to a maximum of 35 mg, administered as an intravenous infusion every two weeks, available in 9 mg and 22 mg vial sizes through specialty distributors.

FDA Approval: Incyte and Syndax Pharmaceuticals announced that the FDA has approved Niktimvo (axatilimab-csfr) for treating chronic graft-versus-host disease (GVHD) in patients who have failed at least two prior therapies, with availability expected in early February.

Dosage Information: Niktimvo is the first FDA-approved treatment targeting CSF-1R for chronic GVHD, administered as an intravenous infusion of 0.3 mg/kg every two weeks, with a maximum dose of 35 mg.

FDA Approval of Niktimvo: The FDA has approved Niktimvo (axatilimab-csfr) as the first treatment for chronic graft-versus-host disease (GVHD) targeting CSF-1R, based on positive results from the AGAVE-201 trial, with availability expected in early February 2025.

Patient Support and Safety Information: Incyte and Syndax are committed to patient support through IncyteCARES, offering financial assistance and education, while also highlighting serious adverse reactions associated with Niktimvo, including infections and infusion-related reactions.

FDA Approval: Incyte and Syndax received FDA approval for Niktimvo in 9 mg and 22 mg vial sizes, intended for treating chronic graft-versus-host disease after failure of at least two prior systemic therapies in patients weighing 40 kg or more.

Market Availability: The companies anticipate that Niktimvo will be available for order in the U.S. starting early February.

FDA Approval of Niktimvo: The FDA has approved Niktimvo (axatilimab-csfr) as the first treatment for chronic graft-versus-host disease (GVHD) targeting CSF-1R, based on positive results from the AGAVE-201 trial, with availability expected in early February 2025.

Patient Support and Safety Information: Incyte and Syndax are committed to patient support through IncyteCARES, offering financial assistance and education, while also highlighting serious adverse reactions associated with Niktimvo, including infections and infusion-related reactions.

Revuforj and Niktimvo Launches: Syndax Pharmaceuticals has launched Revuforj (revumenib) for treating relapsed or refractory acute leukemia with KMT2A translocation, and received FDA approval for Niktimvo (axatilimab) for chronic graft-versus-host disease after prior treatment failures.

Future Plans and Milestones: The company aims to maximize the adoption of Revuforj, submit a supplemental NDA for revumenib in R/R mNPM1 AML by mid-2025, and launch Niktimvo in early 2025, while also presenting data at upcoming medical conferences.

Investigation Announcement: Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Syndax Pharmaceuticals, Inc. regarding possible self-dealing that may affect shareholders' rights.

Call to Action for Shareholders: Long-term SNDX stockholders are encouraged to contact Kuehn Law for a free consultation to discuss potential damages and corporate governance reforms, emphasizing the importance of shareholder involvement in maintaining market integrity.